Draft, not yet released. In stewardship review. Not indexed until the first approved release.

Individualised editing outpaces delivery systems

A conditional statement under stated assumptions, never a prediction.

2 min read0 figures0 tables3 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

Contents
  1. ·Edition home
  2. ·Executive summary
  3. 1Genomics is data infrastructure and a therapeutic frontier
  4. 2Key findings
  5. 3Systems and sectors at baseline
  6. 4Risks and capability
  7. 5Individualised editing outpaces delivery systems
    1. 5.1 Assumptions
    2. 5.2 The cascade, step by step
    3. 5.3 The scenario as a table of steps
  8. 6Readings from the other desks
  9. 7The 2027 agenda
  10. 8Systems in depth
  11. AMethodology
  12. BData appendix
  13. CReferences and record
  14. ·Complete edition, for print

5.1Assumptions

Scenario SCN-XT05-DLV-01: what is assumed, and what is held constant.

Baseline
the 2026 reference state in this edition
Drivers
bespoke editing pathways open faster than payment, manufacturing and oversight capacity grow
Analogues
the 2025 patient-specific therapy and the 2025 trial holds459
Interventions
none modelled: the specification describes the unmitigated case
Run state
narrative specification; quantified run scheduled for 2027

5.2The cascade, step by step

  1. 1

    GOV → HLT

    a plausible mechanism pathway lowers the evidence needed for bespoke therapies

    2025

  2. 2

    HLT → FIN

    payers face one-time prices with thin outcome data

    2026

  3. 3

    INF → HLT

    manufacturing and clinic capacity limit who is treated

    2026

  4. 4

    HLT → GOV

    a safety event in a bespoke or in vivo therapy triggers holds

    2025

  5. 5

    TRD → INF

    trade rules change instrument and reagent supply

    2025

  6. 6

    DAT → FIN

    genetic data and biobanks become assets in disputes over ownership

    2025

5.3The scenario as a table of steps

How the shock in scenario SCN-XT05-DLV-01 would travel through Genomics and Gene Editing’s coupled systems, step by step, under the assumptions the edition states.

StepWhat happensSource
01 Governance to healthA plausible mechanism pathway lowers the evidence needed for bespoke therapies. Analogue or source: 2025.Edition XT-05, scenario SCN-XT05-DLV-01, step 1
02 Health to financePayers face one-time prices with thin outcome data. Analogue or source: 2026.Edition XT-05, scenario SCN-XT05-DLV-01, step 2
03 Infrastructure to healthManufacturing and clinic capacity limit who is treated. Analogue or source: 2026.Edition XT-05, scenario SCN-XT05-DLV-01, step 3
04 Health to governanceA safety event in a bespoke or in vivo therapy triggers holds. Analogue or source: 2025.Edition XT-05, scenario SCN-XT05-DLV-01, step 4
05 Trade to infrastructureTrade rules change instrument and reagent supply. Analogue or source: 2025.Edition XT-05, scenario SCN-XT05-DLV-01, step 5
06 DAT to financeGenetic data and biobanks become assets in disputes over ownership. Analogue or source: 2025.Edition XT-05, scenario SCN-XT05-DLV-01, step 6

A teaching model of a conditional scenario under the edition’s stated assumptions: not a forecast, not a prediction and not a warning. Sources: Genomics and Gene Editing 2026, scenario SCN-XT05-DLV-01 (2026); Genomics and Gene Editing 2026, references (NR-CIT-1) (2026).

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 4Musunuru, K. et al., Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease, New England Journal of Medicine 2025 (abstract read through the Europe PMC record; one infant, two infusions at about 7 and 8 months of age). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.back
  2. 5Clinical Trials Arena (ed.), FDA unveils new pathway to usher bespoke therapies to market (trade press, 13 November 2025; describes the plausible mechanism pathway announced in a journal article by the FDA Commissioner and the CBER Director; secondary report, weak evidence). Clinical Trials Arena, London. Observation year 2025. Accessed 2026-11-03.back
  3. 9BioSpace (ed.), Life-threatening liver toxicity triggers FDA freeze on two Intellia gene therapy studies (trade press, 30 October 2025; relays company disclosures; secondary report, weak evidence). BioSpace, Boston. Observation year 2025. Accessed 2026-11-03.back

Cite this chapter

Valadbaygi, S. (Ed.). (2026). Chapter 5: Individualised editing outpaces delivery systems. In Exponential Technology Report 2026: Genomics and Gene Editing (Baseline Edition 2026, Report No. NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE) [Draft under review]. The Global Centre for Risk and Innovation (GCRI).

Every citation form of the whole report, BibTeX and RIS included, is on the edition home. Cite this report

ReportsContribute

Send evidence or a correction on Genomics and Gene Editing.

Reports is the Consortium’s quarterly publication, written by six desks. This page sits with the Global Centre for Risk and Innovation (GCRI) Systems Evidence desk. What you know about this subject can become evidence, a case or a correction in the next edition, credited to you and published under CC BY 4.0 where it is your own work. Sent to the wrong desk, it is forwarded, not refused.

GCRI Systems Evidence deskExponential Technology

Never send personal data, sensitive infrastructure detail or anything you have no right to share. A contribution is reviewed before use; sending it confers no authorship or editorial rights, and sponsorship never buys a finding.

CC BY 4.0 Free to read. Text and figures: CC BY 4.0. Data: CC0 1.0. Authors keep copyright. Published by GCRI Canada.

The Global Centre for Risk and Innovation

Science · evidence · measurement

Not for profit

Our articles, maps and twins are free to read and free to republish. Readers and partners keep it that way.

Partner with us

Who funds us

GCRI is a not-for-profit institution. To ask who funds a piece of work, use the funding questions form.

Independence

Editors and the expert reviewers named on each article decide what we publish. Funders and partners do not review or approve articles before publication.

Corrections policy

Licence

Articles: CC BY 4.0. Figures, maps, twins and data: CC BY 4.0. Other uses: ask through the permissions form.

Privacy choices